FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
- Top 10 News for 07/21 - 07/25: In the Thick of Earnings; M&A Ramps Up; Where's the Homes?
- Goldman's GOAL Cuts Equities to Neutral, Corporate Credit to Underweight
- Amazon.com, Inc. (AMZN) Posts Q2 Loss of 24c/Share
- IBM (IBM) Rejects Offer for Chip-Making Unit - Bloomberg
- Containerboard Stocks Could Revalue Up to 100% Under MLP Structures, Perry Capital Says (IP) (KS) (RKT)
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
You May Also Be Interested In
- UPDATE: IMF Cuts Global Growth Outlook to 3.4%
- Amicus Therapeutics (FOLD) Gains as Analyst Sees Study 'Success'
- Celsion (CLSN) Calls Data from DIGNITY Study in Breast Cancer 'Very Encouraging'
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!